Literature DB >> 30107167

Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway.

Yonggang Ren1, Jia Tao2, Zhen Jiang1, Dongmei Guo3, Jiancai Tang4.   

Abstract

OBJECTIVE: Wnt/β‑catenin signaling pathway plays important role in colorectal cancer (CRC) and acts as a potential therapeutic target. Pimozide is a FDA-approved clinical drug used to treat psychotic diseases and it has shown anticancer effect in some tumors partially via inhibition of Wnt/β‑catenin signaling pathway. This study aimed to investigate whether pimozide exerts anticancer effect on CRC and explore underlying mechanism. METHODS AND
RESULTS: Pimozide was administrated to treat HCT116 and SW480 cells. Quantitative real-time polymerase chain reaction and western blot were used to detect the expression of epithelial-to-mesenchymal transition markers and Wnt/β‑catenin signaling pathway-related proteins. Cell proliferation and migration were measured by Cell Counting Kit-8 and Transwell assays respectively. HCT116 and SW480 cells were subcutaneously injected into nude mice and when the volume of tumor grown measureable (approximately 100 mm3) animals were treated with vehicle saline or pimozide at a dose of 25 mg/kg·d by oral gavage and then tumor size was measured at 7, 14, 21 and 28 days post treatment. Pimozide dose-dependently inhibited cell proliferation and migration in both HCT116 and SW480 cells, increased expression of E-cadherin and decreased expression of N‑cadherin, vimentin and Snail. In addition, tumor growth was inhibited by pimozide in both HCT116 and SW480 xenografts in vivo. Expression of β‑catenin and Wnt target genes c-Myc, cyclin D1, Axin 2 and survivin was reduced by pimozide treatment in both HCT 116 and SW480 cells.
CONCLUSION: Pimozide exerts anticancer effect in CRC via inhibition of wnt/β‑catenin signaling pathway, suggesting it as a potential therapeutic drug for CRC.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Colorectal cancer; Epithelial-to-mesenchymal transition; Pimozide; Wnt/β‑catenin

Mesh:

Substances:

Year:  2018        PMID: 30107167     DOI: 10.1016/j.lfs.2018.08.027

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.

Authors:  Jerry Harb; Pen-Jen Lin; Jijun Hao
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 2.  Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment.

Authors:  Francesca Battaglin; Priya Jayachandran; Carly Strelez; Annika Lenz; Sandra Algaze; Shivani Soni; Jae Ho Lo; Yan Yang; Joshua Millstein; Wu Zhang; Evanthia T Roussos Torres; Jean C Shih; Shannon M Mumenthaler; Josh Neman; Heinz-Josef Lenz
Journal:  Oncogene       Date:  2022-10-01       Impact factor: 8.756

Review 3.  Research Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer.

Authors:  Qianyang Ni; Meng Li; Suyang Yu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway.

Authors:  Wen Bi; Jiayu Huang; Chunlei Nie; Bo Liu; Guoqing He; Jihua Han; Rui Pang; Zhaoming Ding; Jin Xu; Jiewu Zhang
Journal:  J Exp Clin Cancer Res       Date:  2018-11-13

5.  Pimozide suppresses cancer cell migration and tumor metastasis through binding to ARPC2, a subunit of the Arp2/3 complex.

Authors:  Jiyeon Choi; Yu-Jin Lee; Yae Jin Yoon; Cheol-Hee Kim; Seung-Jin Park; Seon-Young Kim; Nam Doo Kim; Dong Cho Han; Byoung-Mog Kwon
Journal:  Cancer Sci       Date:  2019-11-15       Impact factor: 6.716

6.  Tumor suppressor role of sFRP‑4 in hepatocellular carcinoma via the Wnt/β‑catenin signaling pathway.

Authors:  Quanxin Wu; Cheng Xu; Xianghua Zeng; Zhimin Zhang; Bo Yang; Zhiguo Rao
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 7.  Targeting the Wnt/β-catenin signaling pathway in cancer.

Authors:  Ya Zhang; Xin Wang
Journal:  J Hematol Oncol       Date:  2020-12-04       Impact factor: 17.388

Review 8.  Wnt/β-catenin signaling in cancers and targeted therapies.

Authors:  Fanyuan Yu; Changhao Yu; Feifei Li; Yanqin Zuo; Yitian Wang; Lin Yao; Chenzhou Wu; Chenglin Wang; Ling Ye
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

9.  Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Authors:  Yong Ji; Jian Lv; Di Sun; Yufeng Huang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

Review 10.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.